Inovio Pharmaceuticals Reports 2015 Third Quarter Results

Go back to Inovio Pharmaceuticals Reports 2015 Third Quarter Results

Inovio's (INO) DNA Technology Platform Further Validated with Latest Qtr. Results - Stifel

November 9, 2015 2:46 PM EST

Stifel affirms its Buy rating and $19 price target on Inovio (Nasdaq: INO) following the company's Q3 report and update issued earlier Monday.

Analyst Thomas Shrader, PhD, CFA, noted that EPS of $0.07 was flat with consensus estimates and revenue was driven by... More